Expert Insight

5 catalysts that will impact the future of weight management drugs

The weight management medication market is facing a crucial turning point. Learn about the five game-changing moments that will affect the use of GLP-1s for weight loss — from expanded indications to Medicare coverage — and find out what stakeholders should do now to prepare for the future.

The new wave of weight management medications has the industry divided and stark opinions have already formed. Some argue these products present a paradigm shift to combat the obesity epidemic. Others urge caution, claiming the drugs present a greater risk than reward. A third faction dismiss the products altogether, espousing GLP-1 receptor agonists (GLP-1s) for weight loss as a “vanity drug” trend for the rich.

The real answer is we don’t know yet — the story of GLP-1s for weight loss is yet to be written. Below, we walk through five “catalysts” or game changing moments we’re monitoring over the next one to two years that will influence the future use of weight management medications, organized by how likely we think they are to occur. 


Catalyst 1: FDA approval of new weight management drugs

Weight-management drug competition is ramping up. Though currently only one GLP-1 has been approved for weight management (Novo Nordisk’s semaglutide—also known as Wegovy), early reports from Eli Lilly’s tirzepatide show that the drug may outperform semaglutide in recipients’ percentage of weight loss and percentage of lean muscle mass retained. Furthermore, additional anti-obesity drugs are likely to hit the market in coming years that appeal even more to patients. If the FDA approves these drugs, they will likely have a positive impact on the perception of GLP-1s overall and ease some of the access and price concerns held today.


SPONSORED BY

INTENDED AUDIENCE
  • Health plans
  • Hospitals and health systems
  • Pharmacy and lab

AFTER YOU READ THIS

 

  • You will know the 5 catalysts we’re watching that will influence the future of weight management medications.
  • You will understand the potential ripple effects of these catalysts on the healthcare ecosystem.
  • You will get a taste of what will be covered at the upcoming Clinical Innovation Summit.

AUTHORS

TOPICS

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.